SKYTROFA Market Summary

Key Factors Driving SKYTROFA Growth

1. Once-weekly dosing provides a major convenience advantage: SKYTROFA is a long-acting prodrug of somatropin designed to release unmodified growth hormone over approximately one week, allowing once-weekly subcutaneous administration instead of daily injections. The reduced injection burden is particularly important for children who may require years of GH therapy. A 2025 peer-reviewed review highlighted that daily GH treatment can be affected by injection frequency, pain and practical difficulties, while long-acting GH formulations such as lonapegsomatropin are intended to improve treatment convenience and compliance.

2. Strong pediatric efficacy supports physician adoption: SKYTROFA demonstrated robust growth outcomes in its pivotal pediatric study. FDA data showed an annualized height velocity of 11.2 cm/year with once-weekly SKYTROFA versus 10.3 cm/year with daily somatropin at Week 52, with SKYTROFA demonstrating non-inferiority. The original FDA approval therefore established SKYTROFA as a weekly alternative to established daily GH therapy. Strong efficacy comparable with, and numerically higher than, daily somatropin provides an important foundation for continued switching and new-patient adoption.

3. Expansion into adult growth hormone deficiency significantly broadens the addressable population: In July 2025, the FDA approved SKYTROFA for adults with growth hormone deficiency, marking the product's first major label expansion beyond pediatric GHD. The approval was supported by a Phase III study involving 259 adults with GHD; after 38 weeks, SKYTROFA reduced trunk-body fat by 1.7 percentage points compared with a 0.4-point increase with placebo, a statistically significant treatment difference. Adult GHD therefore provides a substantial additional commercial opportunity beyond the pediatric market.

4. Rapid commercial uptake and substantial revenue base: SKYTROFA generated €206.2 million in revenue in 2025, up from €197.0 million in 2024. Growth accelerated during 2026: Ascendis reported €55.2 million in SKYTROFA revenue in Q2 2026, taking first-half 2026 revenue to €99.2 million. The company also reported more than 20,000 unique SKYTROFA enrollments globally since launch by August 2026, demonstrating substantial patient uptake.

5. Pipeline expansion into additional pediatric growth disorders could materially increase future sales: Ascendis initiated the Phase III HighLiGHts basket trial evaluating SKYTROFA in several additional indications, including idiopathic short stature (ISS), SHOX deficiency, Turner syndrome and small for gestational age (SGA). These populations could considerably expand the product's eligible patient base if successful and subsequently approved. The company has also been evaluating TransCon hGH in combination approaches for achondroplasia and hypochondroplasia, potentially creating another long-term growth avenue.

SKYTROFA Recent Developments

In October 2025, Ascendis Pharma Endocrinology, Inc. announced that SKYTROFA (lonapegsomatropin), its once-weekly growth hormone replacement therapy, is now available in broader dosing ranges in the United States (US) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). The broader ranges are designed to support physicians titrating dosing for adults with GHD who are beginning growth hormone treatment for the first time. SKYTROFA was approved by the US Food and Drug Administration (FDA) for the treatment of adults with GHD, a rare and serious condition, in July 2025 and for the treatment of pediatric GHD in August 2021.

“SKYTROFA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SKYTROFA for approved indication like Somatotropin deficiency; as well as potential indication like Growth disorders, Achondroplasia, and Turner’s syndrome in the 7MM. A detailed picture of SKYTROFA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SKYTROFA for approved and potential indications. The SKYTROFA market report provides insights about SKYTROFA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SKYTROFA performance, future market assessments inclusive of the SKYTROFA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SKYTROFA sales forecasts, along with factors driving its market.

SKYTROFA Drug Summary

SKYTROFA is a long-acting recombinant human growth hormone (rhGH) therapy developed by Ascendis Pharma for the treatment of growth hormone deficiency. It is a prodrug of somatropin designed using Ascendis Pharma’s TransCon technology, in which somatropin is temporarily linked to a carrier molecule that protects it from rapid elimination and is gradually cleaved in the body to release unmodified somatropin. Once released, somatropin binds to growth hormone receptors and stimulates the production of insulin-like growth factor-1 (IGF-1), supporting longitudinal bone growth, protein synthesis, and other physiological processes associated with normal growth and metabolism. SKYTROFA is administered by once-weekly subcutaneous injection, offering a less frequent dosing schedule than conventional daily growth hormone therapies. In the United States, it is approved for the treatment of pediatric patients aged 1 year and older who have growth failure due to inadequate secretion of endogenous growth hormone and for adults with growth hormone deficiency. The product is supplied as a single-dose cartridge designed for use with a compatible delivery device, with dosing individualized according to body weight, age, indication, and clinical response. By providing sustained exposure to growth hormone while releasing the same somatropin molecule used in daily growth hormone replacement, SKYTROFA aims to improve treatment convenience and potentially support adherence in patients requiring long-term growth hormone therapy. The report provides SKYTROFA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the SKYTROFA Market Report

The report provides insights into:

• A comprehensive product overview including the SKYTROFA MoA, description, dosage and administration, research and development activities in approved indications like Somatotropin deficiency; as well as potential indication like Growth disorders, Achondroplasia, and Turner’s syndrome.
• Elaborated details on SKYTROFA regulatory milestones and other development activities have been provided in SKYTROFA market report.
• The report also highlights SKYTROFA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The SKYTROFA market report also covers the patents information, generic entry and impact on cost cut.
• The SKYTROFA market report contains current and forecasted SKYTROFA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SKYTROFA market report also features the SWOT analysis with analyst views for SKYTROFA in approved and potential indications.

Methodology

The SKYTROFA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SKYTROFA Analytical Perspective by DelveInsight

• In-depth SKYTROFA Market Assessment

This SKYTROFA sales market forecast report provides a detailed market assessment of SKYTROFA for approved indication like Somatotropin deficiency; as well as potential indication like Growth disorders, Achondroplasia, and Turner’s syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SKYTROFA sales data uptil 2034.

• SKYTROFA Clinical Assessment

The SKYTROFA market report provides the clinical trials information of SKYTROFA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

SKYTROFA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SKYTROFA Market Potential & Revenue Forecast

• Projected market size for the SKYTROFA and its key indications
• Estimated SKYTROFA sales potential (SKYTROFA peak sales forecasts)
• SKYTROFA Pricing strategies and reimbursement landscape

SKYTROFA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• SKYTROFA Market positioning compared to existing treatments
• SKYTROFA Strengths & weaknesses relative to competitors

SKYTROFA Regulatory & Commercial Milestones

• SKYTROFA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

SKYTROFA Clinical Differentiation

• SKYTROFA Efficacy & safety advantages over existing drugs
• SKYTROFA Unique selling points

SKYTROFA Market Report Highlights

• In the coming years, the SKYTROFA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SKYTROFA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SKYTROFA’s dominance.
• Other emerging products for Somatotropin deficiency; as well as potential indication like Growth disorders, Achondroplasia, and Turner’s syndrome are expected to give tough market competition to SKYTROFA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SKYTROFA in approved and potential indications.
• Analyse SKYTROFA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SKYTROFA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SKYTROFA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of SKYTROFA? How strong is SKYTROFA’s clinical and commercial performance?
• What is SKYTROFA’s clinical trial status in each individual indications such as Somatotropin deficiency; as well as potential indication like Growth disorders, Achondroplasia, and Turner’s syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SKYTROFA Manufacturers?
• What are the key designations that have been granted to SKYTROFA for approved and potential indications? How are they going to impact SKYTROFA’s penetration in various geographies?
• What is the current and forecasted SKYTROFA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SKYTROFA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SKYTROFA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is SKYTROFA? What is the duration of therapy and what are the geographical variations in cost per patient?